Learn About Our Early and Metastatic Breast Cancer Research
With the help of research study participants, we are learning potential new ways to improve Breast Cancer health outcomes.
Learn MoreThis study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy.
Participants must have HR+, HER2- breast cancer
Participants must have breast cancer that is advanced or has spread to another part of the body
Participants must have already received endocrine therapy and a CDK4/6 inhibitor
Participants must have adequate organ function
Participants must be in fair to good health
Participants must be able to swallow capsules/tablets
Participants must not have received chemotherapy or some targeted therapies for advanced breast cancer
Participants must not have cancer that has spread to the brain that has not been treated or is causing symptoms
Participants must not have another serious medical condition
With the help of research study participants, we are learning potential new ways to improve Breast Cancer health outcomes.
Learn MoreLilly has been involved in cancer research for more than fifty years, working to improve the lives of people living with cancer. Learn more about cancer research at Lilly and how you can make an impact.
Learn MoreA clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.